Key statistics
As of last trade Organovo Holdings Inc (0R02:LSE) traded at 0.4512, 0.27% above its 52-week low of 0.45, set on Sep 26, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | 0.4512 |
Low | 0.4512 |
Bid | -- |
Offer | -- |
Previous close | 0.4512 |
Average volume | 2.56k |
---|---|
Shares outstanding | 15.37m |
Free float | 15.05m |
P/E (TTM) | -- |
Market cap | 7.04m USD |
EPS (TTM) | -1.39 USD |
Data delayed at least 15 minutes, as of Oct 09 2024 14:58 BST.
More ▼
Announcements
- Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis
- Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease
- Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)
- Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering
- Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
- Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress
- Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress
- Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results
- CORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and Plan
More ▼